Approved in combination with Bendamustin and Rituximab for R/R DLBCL [66], a randomized phase III trial testing Polatuzumab vedotin in combination with Rituximab and CHP (Cyclophosphamide, Doxorubicin and Prednisone) in nd DLBCL (IPI ≥ 2) vs. R-CHOP was conducted and recently reported [47]. Here, DDIT3 is linked to diffuse large B-cell lymphoma.